PTCy + Sirolimus/VIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation

Summary

This is a single-arm, phase I/II, study of PTCy/sirolimus plus VIC-1911 to prevent GVHD and relapse after Allogeneic Hematopoietic Cell Transplantation (alloHCT).

Timeline

Start

2022-03-17

Primary completion

2024-09-19

Completion

2025-06-30

Publications

• Holtan SG, Grover P, Walton K, El Jurdi N, Quinones V, Maakaron JE, Juckett MB, Bachanova V, Hou JH, Terezakis S, Myers TJ, Paradiso LJ, DeFor TE, Cao Q, Betts BC. Targeting Aurora kinase A to prevent GVHD and relapse after myeloablative allogeneic hematopoietic cell transplantation. Blood Adv. 2026 Apr 14;10(7):2190-2201. doi: 10.1182/bloodadvances.2025017360.

Drugs

Indications